Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00219024 · ClinicalTrials.gov registry record · Phase 3
Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension.
A Phase 3 study of Hypertension, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,775
- Enrollment target
- 2
- Study locations
NCT00219024 is a Phase 3 study of Hypertension that has completed, run by Novartis. The registered enrollment target is 2,775 participants, below the 3,501-participant average among 470 other Hypertension trials with a reported enrollment target (21% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00219024, a Phase 3 study of Hypertension, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,775 participants
- Enrollment target
- 2
- Study locations
Study Summary
To demonstrate the efficacy and safety of aliskiren given to patients with essential hypertension, at doses of 75 mg, 150 mg and 300 mg alone, and in combination with hydrochlorothiazide (HCTZ)
Conditions Studied
Interventions
- DRUG aliskiren
Study Locations (2)
New Jersey
- Novartis Pharmaceuticals - East Hanover
Other
- - Investigative Centers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,775 participants |
| Start Date | 2004-08 |
| Est. Completion | 2005-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00219024
The ClinicalTrials.gov registry entry for NCT00219024 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,775 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,501-participant average among 470 other Hypertension trials with a reported enrollment target (21% lower). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which aliskiren is the first listed.
NCT00219024 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New Jersey, Other.
Frequently Asked Questions
What is clinical trial NCT00219024 about?
NCT00219024 is a clinical study titled "Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension.". To demonstrate the efficacy and safety of aliskiren given to patients with essential hypertension, at doses of 75 mg, 150 mg and 300 mg alone, and in combination with hydrochlorothiazide (HCTZ)
What is the current status of trial NCT00219024?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,775 participants. The study started on 2004-08. Estimated completion is 2005-06.
What conditions does trial NCT00219024 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT00219024?
The interventions under investigation include: aliskiren (DRUG).
Who is sponsoring clinical trial NCT00219024?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00219024 being conducted?
This trial has 2 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.